shutterstock_1201562074_vitalii_vodolazskyi

Vitalii Vodolazskyi / Shutterstock.com

27 January 2022GenericsAlex Baldwin

Virginia judge says court should deny class cert in Zetia antitrust suit

A Virginia district court judge has recommended that buyers of cholesterol drug Zetia (ezetimibe) should not be granted class certification in pay-for-delay litigation against MSD (known as ' Merck & Co' in the US) and Glenmark Generics.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Buyers of Zetia seek class recertification after 4th circ ruling

28 September 2021 Wholesale buyers of MSD’s cholesterol treatment Zetia have asked a Virginia court to recertify their class status and move to trial following a recent fourth circuit ruling that reversed the court’s prior certification.

MSD and Glenmark appeal pay-for-delay Zetia dispute

7 January 2021 Pharmaceutical companies MSD and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia should be reversed because the circumstances of the class members do not justify an award of class status.

More on this story

Buyers of Zetia seek class recertification after 4th circ ruling

28 September 2021 Wholesale buyers of MSD’s cholesterol treatment Zetia have asked a Virginia court to recertify their class status and move to trial following a recent fourth circuit ruling that reversed the court’s prior certification.

MSD and Glenmark appeal pay-for-delay Zetia dispute

7 January 2021 Pharmaceutical companies MSD and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia should be reversed because the circumstances of the class members do not justify an award of class status.

More on this story

Buyers of Zetia seek class recertification after 4th circ ruling

28 September 2021 Wholesale buyers of MSD’s cholesterol treatment Zetia have asked a Virginia court to recertify their class status and move to trial following a recent fourth circuit ruling that reversed the court’s prior certification.

MSD and Glenmark appeal pay-for-delay Zetia dispute

7 January 2021 Pharmaceutical companies MSD and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia should be reversed because the circumstances of the class members do not justify an award of class status.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

USPTO clarifies AI's role in patent eligibility